Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 2 Multiple Myeloma 1 Lymphoma, Follicular 1 Leukemia, Lymphoid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1

Interventions

Rituximab 90 Cyclophosphamide 30 Lenalidomide 28 Bendamustine Hydrochloride 24 Prednisone 20 Vincristine 19 obinutuzumab 17 Doxorubicin 16 fludarabine 14 ibrutinib 13 tazemetostat 9 idelalisib 9 Deoxycholic Acid 9 parsaclisib 8 Prednisolone 8 zanubrutinib 7 venetoclax 7 tofacitinib 7 tisagenlecleucel 5 pembrolizumab 5 ofatumumab 5 ibritumomab tiuxetan 5 duvelisib 5 Gemcitabine 5 Bortezomib 5 durvalumab 4 aflibercept 4 R-CHOP protocol 4 Methylprednisolone 4 Methotrexate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, Follicular × lucatumumab × Clear all

NCT01275209 2020-12-08

LIFT

Novartis

Phase 1 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡